In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Vaccine Market Grows Up: They're Not Just for Kids Anymore

Executive Summary

The adult vaccine market is showing more promise than ever before--and is expected to grow about as fast as pediatric vaccines--as more developers focus on diseases that afflict adults disproportionately or simply strike them in large numbers.

You may also be interested in...



Glaxo Buys A Stake In Intercell And Gains Access To Patch Vaccine Techology

As part of the deal, the big drug maker gets the right to market experimental patch vaccines for traveler's diarrhea and pandemic flu.

Glaxo Buys A Stake In Intercell And Gains Access To Patch Vaccine Techology

As part of the deal, the big drug maker gets the right to market experimental patch vaccines for traveler's diarrhea and pandemic flu.

Provenge Scores In Phase III; Will Dendreon Need To Confirm The IMPACT?

Dendreon's release of positive Phase III results for immunotherapeutic Provenge - including a four-month overall survival benefit compared to placebo - begs the question of whether FDA will now approve the prostate cancer vaccine without a confirmatory trial

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL111109

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel